Full Text View
Tabular View
No Study Results Posted
Related Studies
Inducing Remission in Type 1 Diabetes With Alefacept (T1DAL)
This study is ongoing, but not recruiting participants.
Study NCT00965458   Information provided by National Institute of Allergy and Infectious Diseases (NIAID)

First Received on August 22, 2009.   Last Updated on March 20, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Diabetes Mellitus, Type 1
Additional conditions recognized in this trial
Diabetes Mellitus
More general conditions related to this trial
Autoimmune Diseases
Endocrine System Diseases
Glucose Metabolism Disorders
Immune System Diseases
Metabolic Diseases
Interventions listed in this trial
alefacept
placebo (saline)
More general drug interventions related to this trial
Dermatologic Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
National Institute of Allergy and Infectious Diseases (NIAID)
Immune Tolerance Network (ITN)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services